Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage

Anke Scultetus*, Francoise Arnaud, Lewis Kaplan, Aryeh Shander, Nora Philbin, Jennifer Rice, Richard McCarron, Daniel Freilich

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.

Original languageEnglish
Pages (from-to)59-68
Number of pages10
JournalArtificial Cells, Blood Substitutes, and Biotechnology
Volume39
Issue number2
DOIs
StatePublished - Apr 2011
Externally publishedYes

Keywords

  • HBOC-201
  • hemorrhage
  • pre-hospital trauma care
  • rFVIIa
  • resuscitation

Fingerprint

Dive into the research topics of 'Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage'. Together they form a unique fingerprint.

Cite this